Alzheimer's Disease Clinical Trials

Showing 901-920 of 952 trials

Memantine and Changes of Biological Markers and Brain PET Imaging in Alzheimer's Disease

NCT00800709

In AD, tau protein is abnormally hyperphosphorylated. Significant changes of hyperphosphorylated tau levels in CSF are found in AD patients. It has been shown in vitro that memantine can reverse abnormal hyperphosphorylation of tau in hippocampal neurons of rats. A statistically significant reduction of CSF phosphorylated tau at a preliminary 1-year follow-up was observed, from median 126 (interquartile range 107-153) to 108 (88-133) ng/l (p = 0.018). No statistically significant differences of total tau or Aβ42 were found (Gunnarsson MD, 2007). FDG-PET has the unique ability to estimate the local cerebral metabolic rate of glucose consumption, thus providing information on the distribution of neuronal death and synapse dysfunction in AD in vivo (Herholz K. 2003). Synaptic dysfunction and loss induce a reduction in neuronal energy demand that results in decreased glucose metabolism. Hypometabolism in AD is thought to reflect loss of synaptic activity and density (Herholz K. 2003; Mielke R, et al. 1998). Another biological markers such as inflammatory factor and APOEε4 also play a part in the onset of AD (Glodzik-Sobanska L, 2007).

Alzheimer's Disease

Shanghai Mental Health Center26 participantsStarted Jul 2008

Shanghai, Shanghai Municipality, China

TERMINATEDPHASE1

Study of Uptake, Break Down and Elimination of an Investigational Drug in Healthy Volunteers

NCT00777361

This study is being performed in order to learn more about a new drug (possible as treatment for people with Alzheimer's Disease and other conditions with cognitive dysfunction (memory and attention problems)) and how it is handled by the body by giving the drug to healthy volunteers with different genotypes.

Alzheimer's Disease

AstraZeneca9 participantsStarted Oct 2008

Macclesfield, Cheshire, United Kingdom

COMPLETEDPHASE1

A Safety and Tolerability Study of ABT-126 in Elderly

NCT00867399

The objectives of this study are to assess the safety, tolerability and pharmacokinetics of ABT-126 in elderly subjects.

Alzheimer's Disease

Abbott30 participantsStarted Mar 2009

Orlando, Florida, United States

Memantine and Changes of Biological Markers and Brain PET Imaging in Alzheimer's Disease

Study of Uptake, Break Down and Elimination of an Investigational Drug in Healthy Volunteers

A Safety and Tolerability Study of ABT-126 in Elderly

Related Searches

Safety/Tolerability, Immunological and Clinical Activity of a Boost Immunization With AFFITOPE AD02

Lighthouse Project on Dementia, Ulm, Germany

Reuptake of an E-Learning Programme in General Practice

SPECT/CT in the Diagnosis of Dementia

Project COPE:Managing Dementia at Home

A Multi-Center, Randomized, Double-Blind, Parallel Group Study With 3 Groups Receiving Placebo, 5 mg of E2020 and 10 mg of E2020

Disease-modifying Properties of Lithium in the Neurobiology of Alzheimer's Disease

Amyloid Plaque and Tangle Imaging in Alzheimer's Disease and Down Syndrome

Implications of Amyloid Pathology

Memory Aid for Informed Consent in Alzheimer's Research

Memory Impairment Study (Mild Cognitive Impairment Study)

Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP)

Curcumin in Patients With Mild to Moderate Alzheimer's Disease

A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers

Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia

The Use of Reminders in Implementing an E-learning Program in General Practice

Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers